{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:30:47Z","timestamp":1761895847864},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T00:00:00Z","timestamp":1398211200000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Sanofi-Aventis Australia Pty Ltd"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Weight gain and hypoglycaemia are common adverse effects associated with anti\u2010diabetic treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>Our aim was to evaluate the long\u2010term effects of adjunctive exenatide therapy on weight loss and glycaemic control in patients with type 2 diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A review of medical records in a specialist diabetes clinic over 5 years identified 446 patients who were prescribed exenatide therapy. We examined change in glycosylated haemoglobin (<jats:styled-content style=\"fixed-case\">HbA<jats:sub>1c<\/jats:sub><\/jats:styled-content>), weight, albumin\u2010creatinine ratio and hypoglycaemic medication during 24 months follow up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Subjects were aged 59 \u00b1 10 years (49% women) and received exenatide in combination with oral agents and insulin (47%). During an average of 17 \u00b1 14 months follow up, 51% (more women than men; odds ratio 1.69, 95% confidence interval 1.14\u20132.49) remained on treatment. Lack of efficacy (33%) and\/or gastrointestinal (27%) side\u2010effects were the main reasons for treatment cessation. At 24 months, there was a reduction in HbA<jats:sub>1c<\/jats:sub> of 0.7 \u00b1 1.2% and weight loss of 4.3 \u00b1 5.2\u2009kg. Change in <jats:styled-content style=\"fixed-case\">HbA<jats:sub>1c<\/jats:sub><\/jats:styled-content> was similar regardless of concurrent insulin therapy, yet insulin was associated with greater weight reduction (4.8 \u00b1 5.3 vs 3.8 \u00b1 5.1\u2009kg, <jats:italic>P<\/jats:italic> = 0.016). Independent predictors of <jats:styled-content style=\"fixed-case\">HbA<jats:sub>1c<\/jats:sub><\/jats:styled-content> response were higher baseline <jats:styled-content style=\"fixed-case\">HbA<jats:sub>1c<\/jats:sub><\/jats:styled-content>, longer duration of diabetes and use of insulin or sulfonylureas at study end. Predictors of weight response were baseline use of insulin or thiazolidinediones, increased age, female sex and sulfonylurea or thiazolidinediones at study end. Longer exenatide treatment duration was favourable for reducing <jats:styled-content style=\"fixed-case\">HbA<jats:sub>1c<\/jats:sub><\/jats:styled-content> and weight.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Exenatide is effective in reducing <jats:styled-content style=\"fixed-case\">HbA<jats:sub>1c<\/jats:sub><\/jats:styled-content> and weight, regardless of concurrent insulin, and in a specialist diabetes outpatient clinic, is recommended for use in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.12377","type":"journal-article","created":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T10:20:41Z","timestamp":1392632441000},"page":"345-353","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long\u2010term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic"],"prefix":"10.1111","volume":"44","author":[{"given":"M. J.","family":"Carrington","sequence":"first","affiliation":[{"name":"Preventative Health and NHMRC Centre of Research Excellence to Reduce Inequality in Heart Disease Baker IDI Heart and Diabetes Institute  Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.\u2010K.","family":"Chan","sequence":"additional","affiliation":[{"name":"Preventative Health and NHMRC Centre of Research Excellence to Reduce Inequality in Heart Disease Baker IDI Heart and Diabetes Institute  Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Preventative Health and NHMRC Centre of Research Excellence to Reduce Inequality in Heart Disease Baker IDI Heart and Diabetes Institute  Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Sjouke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Academic Medical Centre  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Brazilek","sequence":"additional","affiliation":[{"name":"Central Medical School Monash University  Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Diabetes Clinical Services Baker IDI Heart and Diabetes Institute  Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4,23]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"The Diabetes Atlas","author":"IDF","year":"2008"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.5.1047"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.10.1499"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-8-200510180-00006"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9025"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-11-9"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2009.07.008"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802418851"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.90222.2008"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/db05-0996"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2009.245"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X253870"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00589.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0510-2"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1521"},{"issue":"468","key":"e_1_2_7_17_1","first-page":"e9","article-title":"Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes","volume":"123","author":"Apovian CM","year":"2010","journal-title":"Am J Med"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-2-201101180-00300"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60590-9"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60659-0"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01154.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.1092"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.11.2628"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.1083"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01393.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2012.10217"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.07.021"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimj.12377","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimj.12377","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.12377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T11:28:48Z","timestamp":1696159728000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.12377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1111\/imj.12377"],"URL":"https:\/\/doi.org\/10.1111\/imj.12377","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"2013-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-01-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}